These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 35070881

  • 21. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW, Lee HM, Choi SE, Yoo H, Ahn SG, Lee MK, Jeong J, Jung WH.
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [Abstract] [Full Text] [Related]

  • 22. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
    Corben AD, Abi-Raad R, Popa I, Teo CH, Macklin EA, Koerner FC, Taghian AG, Brachtel EF.
    Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
    [Abstract] [Full Text] [Related]

  • 23. Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore.
    Laas E, Labrosse J, Hamy AS, Benchimol G, de Croze D, Feron JG, Coussy F, Balezeau T, Guerin J, Lae M, Pierga JY, Reyal F.
    Br J Cancer; 2021 Apr; 124(8):1421-1427. PubMed ID: 33558711
    [Abstract] [Full Text] [Related]

  • 24. Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with Miller-Payne grade 4 following neoadjuvant chemotherapy.
    Ma J, Deng Y, Chen D, Li X, Yu Z, Wang H, Zhong L, Li Y, Wang C, Li X, Yu J, Zhang Q.
    NPJ Breast Cancer; 2023 Jul 12; 9(1):57. PubMed ID: 37438419
    [Abstract] [Full Text] [Related]

  • 25. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A, Wengert GJ, Helbich TH, Bago-Horvath Z, Alaei S, Bartsch R, Dubsky P, Baltzer P, Clauser P, Kapetas P, Morris EA, Meyer-Baese A, Pinker K.
    Invest Radiol; 2019 Feb 12; 54(2):110-117. PubMed ID: 30358693
    [Abstract] [Full Text] [Related]

  • 26. Comparative study of pathological response evaluation systems after neoadjuvant chemotherapy for breast cancer: developing predictive models of multimodal ultrasound features including shear wave elastography combined with puncture pathology.
    Duan Y, Song X, Guan L, Wang W, Song B, Kang Y, Jia Y, Zhu Y, Nie F.
    Quant Imaging Med Surg; 2023 May 01; 13(5):3013-3028. PubMed ID: 37179914
    [Abstract] [Full Text] [Related]

  • 27. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
    Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY.
    Breast Cancer Res Treat; 2016 Dec 01; 160(3):475-489. PubMed ID: 27730423
    [Abstract] [Full Text] [Related]

  • 28. Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.
    Candelaria RP, Bassett RL, Symmans WF, Ramineni M, Moulder SL, Kuerer HM, Thompson AM, Yang WT.
    Oncologist; 2017 Apr 01; 22(4):394-401. PubMed ID: 28314842
    [Abstract] [Full Text] [Related]

  • 29. Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival.
    Sutton TL, Schlitt A, Gardiner SK, Johnson N, Garreau JR.
    J Surg Oncol; 2020 Dec 01; 122(8):1761-1769. PubMed ID: 33125715
    [Abstract] [Full Text] [Related]

  • 30. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
    Morales Murillo S, Gasol Cudos A, Veas Rodriguez J, Canosa Morales C, Melé Olivé J, Vilardell Villellas F, Sanchez Guzman DR, Iglesias Martínez E, Salud Salvia A.
    Breast; 2021 Apr 01; 56():35-41. PubMed ID: 33601299
    [Abstract] [Full Text] [Related]

  • 31. Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.
    Müller HD, Posch F, Suppan C, Bargfrieder U, Gumpoldsberger M, Hammer R, Hauser H, Dandachi N, Prein K, Stoeger H, Lax S, Balic M.
    Ann Surg Oncol; 2019 Dec 01; 26(13):4274-4283. PubMed ID: 31452052
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
    Takahashi Y, Iwamoto T, Suzuki Y, Kajiwara Y, Hatono M, Tsukioki T, Kawada K, Kochi M, Ikeda H, Shien T, Taira N, Matsuoka J, Doihara H, Toyooka S.
    Clin Breast Cancer; 2020 Apr 01; 20(2):117-124.e4. PubMed ID: 31570267
    [Abstract] [Full Text] [Related]

  • 33. A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
    Zhu M, Liang C, Zhang F, Zhu L, Chen D.
    Front Oncol; 2021 Apr 01; 11():690336. PubMed ID: 34745934
    [Abstract] [Full Text] [Related]

  • 34. Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity.
    Suppan C, Posch F, Mueller HD, Mischitz N, Steiner D, Klocker EV, Setaffy L, Bargfrieder U, Hammer R, Hauser H, Jost PJ, Dandachi N, Lax S, Balic M.
    Cancers (Basel); 2021 May 20; 13(10):. PubMed ID: 34065332
    [Abstract] [Full Text] [Related]

  • 35. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA, Arrazola García J, García-Sáenz JA, Furió-Bacete V, Fuentes Ferrer ME, Ortega Candil A, Cabrera Martín MN, Carreras Delgado JL.
    Rev Esp Med Nucl Imagen Mol; 2014 May 20; 33(1):14-21. PubMed ID: 23809513
    [Abstract] [Full Text] [Related]

  • 36. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
    Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MTDF, Wesseling J, Lips EH, Sonke GS.
    Clin Cancer Res; 2019 Aug 15; 25(16):4985-4992. PubMed ID: 31076546
    [Abstract] [Full Text] [Related]

  • 37. RS7435335 located in the UGT2B7 gene may be a possible genetic marker for the clinical response and prognosis of breast cancer patients receiving neoadjuvant chemotherapy.
    Mou P, Wang H, An L, Yin Q, Chang J.
    J Cell Biochem; 2019 May 15; 120(5):7167-7173. PubMed ID: 30552707
    [Abstract] [Full Text] [Related]

  • 38. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J.
    J Cell Mol Med; 2020 Mar 15; 24(5):2993-3021. PubMed ID: 31989747
    [Abstract] [Full Text] [Related]

  • 39. Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer.
    Wei B, Shan Y, Du Z, Yin C, Zhang Q, Lin H, Zhang G, Song D, Zuo H.
    Appl Biochem Biotechnol; 2022 Sep 15; 194(9):3961-3973. PubMed ID: 35579744
    [Abstract] [Full Text] [Related]

  • 40. Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.
    Zuo WJ, He M, Zheng H, Liu Y, Liu XY, Jiang YZ, Wang ZH, Lu RQ, Shao ZM.
    Gland Surg; 2021 Apr 15; 10(4):1300-1314. PubMed ID: 33968682
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.